



FEB 16 1999

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

R. Stewart Campbell, Ph.D.  
Technical Director  
Quantase Ltd.  
3 Riverview Business Park  
Friarton Road  
Perth PH2 8DF  
Scotland, UK

Re: K984463  
Trade Name: Quantase™ PHE/GAL Screening Assay  
Regulatory Class: II, I  
Product Code: 75 JNB, 75 JIA, 75 JIX, 75 JJY  
Dated: December 10, 1998  
Received: December 16, 1998

Dear Dr. Campbell:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.


Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>"

Sincerely yours,



Steven I. Gutman, M.D., M.B.A.  
Director  
Division of Clinical Laboratory Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

510(k) Number (if known): K984463

Device Name: QUANTASE™ PHE/GAL  
SCREENING ASSAY

**Indications For Use:**

The Quantase Phe/Gal Screening Assay is an enzymatic colorimetric end-point method for the determination of L-phenylalanine and total D(+)galactose (D(+)galactose + galactose-1-phosphate) in dried blood spot specimens taken from newborn human infants as part of a newborn screening program.

The test is intended as a screening method for measuring the L-phenylalanine and total D(+)galactose concentrations in newborn blood spot specimens. Elevated results are not diagnostic *per se* of phenylketonuria or galactosemia, but indicate the urgent need for further study of the newborn from which the presumptive positive specimen was received.

The kit is NOT intended for use in monitoring the circulating concentrations of L-phenylalanine and total D(+)galactose in phenylketonuric and galactosemic patients respectively, nor to detect ante-natal phenylketonuria and galactosemia or maternal phenylketonuria

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

**Concurrence of CDRH, Office of Device Evaluation (ODE)**

Sean Coogan  
(Division Sign-Off)  
Division of Clinical Laboratory Devices  
510(k) Number K984463

Prescription Use   
(Per 21 CFR 801.109)

OR

Over-The-Counter Use

(Optional Format 1-2-96)